Key result
Amphilimus-eluting stents (Cre8 EVO) were evaluated for target lesion failure rates across selected randomized trials of patients with coronary artery disease and diabetes mellitus.
Why the study?
Do amphilimus-eluting stents improve target lesion failure rates in patients with coronary artery disease and diabetes mellitus?
Do amphilimus-eluting stents improve target lesion failure rates in patients with coronary artery disease and diabetes mellitus?
This editorial discusses the performance of amphilimus-eluting stents (Cre8 EVO) regarding target lesion failure in patients with diabetes mellitus across selected randomized trials.
(A) Profiles of investigational and comparator device in the SUGAR trial; (B) target lesion failure rates in selected randomized trials of Cre8 EVO. Studies investigating only patients with diabetes are highlighted with a blue background; other trials investigated patients with and without diabetes. *Target lesion failure (TLF) rates displayed here are additive incidences of individual TLF components. Composite incidence of TLF in both groups could have been lower.
No takes yet. Share an insight, caveat, or question.
Byrne et al. (2021) conducted an editorial in Coronary artery disease and diabetes mellitus. Amphilimus-eluting stents (Cre8 EVO) was evaluated on Target lesion failure (TLF). Amphilimus-eluting stents (Cre8 EVO) were evaluated for target lesion failure rates across selected randomized trials of patients with coronary artery disease and diabetes mellitus.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: